fc026bd121
Pipeline auto-fixer: removed [[ ]] brackets from links that don't resolve to existing claims in the knowledge base.
4.9 KiB
| type | title | author | url | date | domain | secondary_domains | format | status | priority | tags | intake_tier | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| source | JMCP 2026: Real-World GLP-1 Medicaid Persistence 60.8% at 6 Months — Tirzepatide 71.7% vs Semaglutide 56.5%; Cost #1 Discontinuation Driver | Journal of Managed Care & Specialty Pharmacy | https://www.jmcp.org/doi/full/10.18553/jmcp.2026.32.3.271 | 2026-03-01 | health | research-paper | unprocessed | medium |
|
research-task |
Content
Real-world 6-month persistence and adherence data from a Medicaid population (JMCP, 2026, Vol. 32, No. 3).
Persistence rates:
- Overall GLP-1 (semaglutide): 60.8% at 6 months
- GLP-1/GIP (tirzepatide): 60.1% at 6 months (same overall)
- Tirzepatide specifically: 71.7% persistence and 69.9% adherence
- Semaglutide specifically: 56.5% persistence and 55.9% adherence
Key driver of discontinuation:
- Cost is #1 reason for discontinuation
- Financial barriers account for nearly half of all discontinuations in some cohorts
- Adverse effects and perceived lack of efficacy are secondary reasons
Tirzepatide vs. semaglutide:
- Tirzepatide has 15 percentage point higher persistence (71.7% vs 56.5%)
- Possible mechanism: tirzepatide's dual GLP-1/GIP mechanism may produce better tolerability and efficacy, reducing discontinuation
- OR: tirzepatide is newer (2023 approval) and attracts more motivated patients — selection bias possible
Context:
- Medicaid population (lower income, higher chronic disease burden)
- 6-month timeframe — not 12-month durability data
- Companion behavioral programs not measured in this study
Agent Notes
Why this matters: This is the real-world Medicaid data showing that COST — not efficacy and not side effects — is the primary barrier to GLP-1 persistence. This directly challenges any framing that adherence failure is a patient behavior problem. The barrier is structural (drug price), not behavioral. This is also the lowest-income population data point — the most relevant for understanding population-health impact, since GLP-1 benefits the chronic disease populations that are also lower-income.
What surprised me: The 15 percentage point gap between tirzepatide (71.7%) and semaglutide (56.5%) in Medicaid. This is larger than I expected from a comparator study. If tirzepatide's better persistence translates to better outcomes in this population, the drug formulary/cost structure for Medicaid becomes a significant health equity issue.
What I expected but didn't find: 12-month data. The 6-month data is useful but the durability question (does anyone stay on >1 year in Medicaid?) remains unanswered here.
KB connections:
- GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035 — cost as #1 discontinuation reason is evidence the chronic use model isn't sticking in low-income populations
- SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent — cost barrier to GLP-1 access is an SDOH problem (financial security = social determinant)
- medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate — GLP-1 is one of the rare clinical interventions that addresses metabolic disease, but its impact is limited by access barriers that are fundamentally SDOH
Extraction hints:
- Consider enriching existing GLP-1 claim with this Medicaid persistence data and cost barrier finding
- The cost-as-barrier finding is politically significant: if cost is the primary driver, then drug price negotiation/rebate structure determines population health impact more than clinical factors
- The tirzepatide vs. semaglutide persistence gap (71.7% vs. 56.5%) could be a standalone claim if confirmed at 12 months
Context: First major Medicaid-population real-world GLP-1 persistence study. This population (low-income, high chronic burden) is the most affected by the GLP-1 cost problem. The data confirms what was suspected: those who most need the drug are least able to sustain access.
Curator Notes (structured handoff for extractor)
PRIMARY CONNECTION: GLP-1 receptor agonists are the largest therapeutic category launch... — specifically the adherence/chronic use model problem WHY ARCHIVED: Medicaid real-world persistence data is the most relevant population for understanding whether GLP-1 can address the population-level chronic disease burden; cost-as-barrier finding challenges any claim that adherence is primarily behavioral EXTRACTION HINT: The structural insight is that cost — not behavior — determines persistence in the lowest-income, highest-chronic-disease population. This has policy implications (drug pricing, Medicaid formulary design) more than clinical implications.